- FDA U-turn triggers crash: uniQure (NASDAQ: QURE) shares fell over 50% in one day after U.S. regulators said current clinical data for its experimental Huntington’s disease gene therapy is not adequate for approvalreuters.com. This reversal comes just weeks after uniQure’s trial results were hailed as “game-changing”1 .
- Wild price swing: QURE stock plummeted from about $68 to the low-$30s, erasing roughly half of its market value (now ~$2.1 B)stockanalysis.com. It hit an intraday low near $23 before partially rebounding to ~$34stockinvest.us, still down ~54% on the news2 .
- Surprise FDA setback: The FDA no longer agrees that uniQure’s Phase 1/2 data (with external control) can support a BLA (marketing application) under accelerated approvalreuters.com – a “drastic change” from prior guidance, uniQure’s CEO saidglobenewswire.com. The timeline for approval is now unclear, likely delaying any U.S. launch beyond 20263 .
- Analyst reactions: Experts call this a major regulatory setbackreuters.com. Guggenheim’s analyst noted the FDA now sees uniQure’s analysis as “post hoc” (not pre-specified)reuters.com, and another analyst warned new trials or data may be neededreuters.com. Some have cut price targets (e.g. one lowered from $76 to $53benzinga.com), though the pre-news consensus target was ~$68 with a Strong Buy rating4 .
- Investor sentiment & fallout: The shock has rattled biotech investors – uniQure’s stock had soared ~300% in September after positive trial datafiercebiotech.com, and now enthusiasm has flipped to disappointment. Shareholder rights law firms quickly launched investigations for potential securities fraud (citing the 57% one-day plunge)businesswire.combusinesswire.com, reflecting investor outrage.
- Technical picture: Technically, QURE is in free-fall territory. The gap-down left no clear support levels; shares traded in a wide ~$22–$36 range on the crash daystockinvest.us. Volume spiked to ~30 million shares (vs. ~1–2 million typical), indicating intense selling pressurestockinvest.us. The stock is now well below key moving averages (which sit around $52–$62)5
UniQure Stock Plunges 50% on FDA Shocker – What’s Next for QURE’s Gene Therapy Ambitions?
Stock Market Today
BHP share price in focus as Cyclone Mitchell shuts Pilbara iron ore ports ahead of earnings
SYDNEY, Feb 8, 2026, 16:48 AEDT — Market closed. BHP Group shares are back in focus for Monday after Tropical Cyclone Mitchell strengthened off Western Australia and shut a string of Pilbara ports, including Port Hedland. The storm was upgraded to Category 3 with gusts of up to 195 kph, and forecasters said it could make landfall late Sunday or early Monday. 1 That matters now because the Pilbara is the main export route for BHP’s iron ore, the miner’s biggest earner. If the shutdown drags on, cargo schedules slip, traders start pencilling in missed tonnes, and prices can jump
Northern Star share price: what to watch before ASX reopens as FY26 results near
Northern Star Resources closed at A$26.77, down 1.7% Friday, after receiving a A$50 million cash payment from MGX for a Northern Territory project stake. Shares have fallen 7.5% over five sessions ahead of FY26 half-year results due pre-open Feb. 12, with management set to brief investors later that morning.
Stock Market Today 08.02.2026
LIVEMarkets rolling coverageStarted: February 8, 2026, 12:00 AM ESTUpdated: February 8, 2026, 1:12 AM EST Crude Oil Prices Rise Amid Dollar Weakness and Middle East Geopolitical Tensions February 8, 2026, 1:12 AM EST. Crude oil prices gained as the U.S. dollar weakened and geopolitical tensions escalated in the Middle East. March WTI crude futures rose 0.41%, supported by doubts over a breakthrough in U.S.-Iran nuclear talks. Iran's stance on uranium enrichment keeps supply risks high amid potential military strikes. Positive U.S. consumer sentiment also supported demand outlook. President Trump's statements about readiness to act militarily and tariff rollbacks on India
Tower Semiconductor stock jumps again on Nvidia optics tie-up as earnings near
Tower Semiconductor shares rose 7.7% to $139.04 Friday after announcing a collaboration with Nvidia on AI data-center networking. The stock touched $141 intraday and gained another 1% after hours. Investors await Tower’s Feb. 11 earnings for details on its silicon photonics work. No financial terms or shipment timeline were disclosed.
